Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E

Charles H. Hatheway, John D. Snyder, Jerry E. Seals, Timm A. Edell, George E. Lewis

Research output: Contribution to journalArticle

Abstract

Serum levels of equine-botulism antitoxin to toxin types A, B, and E were measured in four type-A botulism patients who had received equine-botulism antitoxin. High circulating levels capable of neutralizing in excess of 1 x 108, 9 x 107, and 6 x 106 50% mouse lethal doses of toxin of types A, B, and E, respectively, were detected. There was little depletion of type-A antitoxin even though two of the patients had circulating type-A toxin before treatment. The half-life for antitoxin persistence for one patient was calculated as being 6.5, 7.6, and 5.3 days for antitoxin types A, B, and E, respectively. Antitoxin levels were not proportionate to the amount (range, 2-4 vials) injected and did not appear to be affected by whether the route of administration was iv or im. Peak serum levels of antitoxin were 10-1,000 times higher than amounts needed to neutralize the toxin measured in the serum of these and other patients with botulism.

Original languageEnglish (US)
Pages (from-to)407-412
Number of pages6
JournalJournal of Infectious Diseases
Volume150
Issue number3
DOIs
StatePublished - Jan 1 1984

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E'. Together they form a unique fingerprint.

  • Cite this